B+
Bull case
30%
Probability
Target price
$125.00
Analysis reference price unavailable
Analysis 2026-09-07 · RankAlpha Sentiment Codex
HALO
Halozyme TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Record royalty growth, raised 2026 guidance, collaboration momentum, and substantial share repurchases support a positive operating thesis. The platform's value could compound if new partner programs launch successfully.
Posture
Constructive
Lead driver
Sentiment
What changed
3 setup hits (3d) with net bullish as of 2026-09-09.
What can break
CEO Form 4 filings show open-market sales on August 17-18; this is a sentiment signal only and not evidence about operating results [#SEC-FORM4-2026-08-19].
Momentum
94
Value
66
Sentiment
63
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $105.00 · Bull $125.00 · Bear $85.00Analysis 2026-09-07; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-07 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bullish
Target $99.56
Why
Momentum94 · Δ7d +1.3
Value66 · Δ7d 0.0
Sentiment63 · Δ7d +1.7
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Confirming evidence
- • 3 setup hits (3d) with net bullish as of 2026-09-09.
- • Sentiment remains the lead driver in the composite, 7D delta +1.7.
Contradictions & invalidation
- • CEO Form 4 filings show open-market sales on August 17-18; this is a sentiment signal only and not evidence about operating results [#SEC-FORM4-2026-08-19].
- • Expectations risk: the stock is above the available analyst median target, with target breadth and revision data unavailable.
- • The Q2 beat and guidance raise appear substantially reflected in the price, while long-dated collaboration opportunities depend on partner development, regulatory approvals, launches, and continued deal cadence.
Catalyst clock
2026-08-06
Q2 2026 beat and raised guidance [#SEC-8K-2026-08-06]
Lead driver: Sentiment · See AI snapshot
Momentum
94
9% active weight
Current posture
7d trendImproving
Δ7d
+1.3
Δ21d
-1.0
Value
66
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+1.7
Sentiment
63
62% active weight
Current posture
7d trendImproving
Δ7d
+1.7
Δ21d
+5.6
Why this grade
Composite grade B. Momentum 94.0 / Value 66.2 / Sentiment 63.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-07. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$105.00
Analysis reference price unavailable
Analysis 2026-09-07 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$85.00
Analysis reference price unavailable
Analysis 2026-09-07 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$11.69B
Beta
0.97
Shares Out
113.5M
P/E (TTM)
15.0
P/S (TTM)
6.74
P/FCF (TTM)
13.90
Rev YoY
+47.7%
EPS YoY
+42.6%
Gross Margin
+76.4%
Op Margin
+56.8%
Net Debt
$2.03B
Current Ratio
2.71
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data